Prevention and Treatment of Cancer-Related Infections

Restricted access

Patients with cancer are at increased risk for developing infectious complications during the course of their disease and treatment. The following sections of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections provide an overview of the risk factors for infectious complications, recommendations for infectious risk categorization, and strategies for prevention of infections in high-risk patient populations with cancer. Individualized risk evaluation for infections and incorporation of preventative measures are essential components of the overall spectrum of cancer care, and may contribute to optimizing treatment outcomes for patients.

  • 1

    Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000;88:17101714.

    • Search Google Scholar
    • Export Citation
  • 2

    Freifeld AG, Walsh T, Marshall D. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165176.

    • Search Google Scholar
    • Export Citation
  • 3

    Hidalgo M, Hornedo J, Lumbreras C. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213219.

    • Search Google Scholar
    • Export Citation
  • 4

    Hughes WT, Armstrong D, Bodey GP. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730751.

    • Search Google Scholar
    • Export Citation
  • 5

    Kern WV, Cometta A, De Bock R. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999;341:312318.

    • Search Google Scholar
    • Export Citation
  • 6

    Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:10921096.

    • Search Google Scholar
    • Export Citation
  • 7

    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:13231332.

  • 8

    Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996;10:223237.

    • Search Google Scholar
    • Export Citation
  • 9

    Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:1320.

  • 10

    Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:25612568.

    • Search Google Scholar
    • Export Citation
  • 11

    Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316322.

    • Search Google Scholar
    • Export Citation
  • 12

    Talcott JA, Whalen A, Clark J. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107114.

    • Search Google Scholar
    • Export Citation
  • 13

    Mihu CN, Schaub J, Kesh S. Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation: a single-institution, nested case-controlled study. Biol Blood Marrow Transplant 2008;14:14291433.

    • Search Google Scholar
    • Export Citation
  • 14

    Neofytos D, Horn D, Anaissie E. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265273.

    • Search Google Scholar
    • Export Citation
  • 15

    Rizzo JD, Wingard JR, Tichelli A. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006;12:138151.

    • Search Google Scholar
    • Export Citation
  • 16

    Sullivan KM, Dykewicz CA, Longworth DL. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 2001:392421.

    • Search Google Scholar
    • Export Citation
  • 17

    Griffiths H, Lea J, Bunch C. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1992;89:374377.

  • 18

    Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982;96:4750.

  • 19

    Molteni A, Nosari A, Montillo M. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematologica 2005;90:11451147.

    • Search Google Scholar
    • Export Citation
  • 20

    Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94:20332039.

    • Search Google Scholar
    • Export Citation
  • 21

    DiNubile MJ. Fever and neutropenia: still a challenge. Contemp Intern Med 1995;7:3537.

  • 22

    Freifeld AG, Bow EJ, Sepkowitz KA. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e5693.

    • Search Google Scholar
    • Export Citation
  • 23

    Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 2004;39(Suppl 1):S4448.

    • Search Google Scholar
    • Export Citation
  • 24

    Gerson SL, Talbot GH, Hurwitz S. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345351.

    • Search Google Scholar
    • Export Citation
  • 25

    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328340.

    • Search Google Scholar
    • Export Citation
  • 26

    Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256264.

  • 27

    Engelhard D, Elishoov H, Or R. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 1995;16:565570.

    • Search Google Scholar
    • Export Citation
  • 28

    Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996;15:291296.

    • Search Google Scholar
    • Export Citation
  • 29

    Rossetti F, Cesaro S, Putti MC, Zanesco L. High-dose cytosine arabinoside and viridans streptococcus sepsis in children with leukemia. Pediatr Hematol Oncol 1995;12:387392.

    • Search Google Scholar
    • Export Citation
  • 30

    Chen YK, Hou HA, Chow JM. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 2011.

    • Search Google Scholar
    • Export Citation
  • 31

    Epstein JB, Hancock PJ, Nantel S. Oral candidiasis in hematopoietic cell transplantation patients: an outcome-based analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:154163.

    • Search Google Scholar
    • Export Citation
  • 32

    Kalhs P, Kier P, Lechner K. Functional asplenia after bone marrow transplantation. Ann Intern Med 1990;113:805806.

  • 33

    Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule—United States, 2010. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 34

    Anaissie EJ, Kontoyiannis DP, O’Brien S. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559566.

    • Search Google Scholar
    • Export Citation
  • 35

    Morrison VA, Rai KR, Peterson BL. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001;19:36113621.

    • Search Google Scholar
    • Export Citation
  • 36

    Anaissie E, Kontoyiannis DP, Kantarjian H. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992;117:466469.

    • Search Google Scholar
    • Export Citation
  • 37

    O’Brien S, Kantarjian H, Beran M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:16951700.

    • Search Google Scholar
    • Export Citation
  • 38

    Genzyme Corporation. Prescribing Information. Campath (alemtuzumab) Injection for Intravenous Use. Available at: http://www.campath.com/pdfs/2009-08-Campath%20US%20PI.pdf. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 39

    Hillmen P, Skotnicki AB, Robak T. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:56165623.

    • Search Google Scholar
    • Export Citation
  • 40

    Moreton P, Kennedy B, Lucas G. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:29712979.

    • Search Google Scholar
    • Export Citation
  • 41

    Stilgenbauer S, Zenz T, Winkler D. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:39944001.

    • Search Google Scholar
    • Export Citation
  • 42

    Keating MJ, Flinn I, Jain V. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:35543561.

    • Search Google Scholar
    • Export Citation
  • 43

    Thursky KA, Worth LJ, Seymour JF. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006;132:312.

    • Search Google Scholar
    • Export Citation
  • 44

    Laurenti L, Piccioni P, Cattani P. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 45

    Nguyen DD, Cao TM, Dugan K. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002;3:105110.

    • Search Google Scholar
    • Export Citation
  • 46

    O’Brien S, Ravandi F, Riehl T. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:18161819.

    • Search Google Scholar
    • Export Citation
  • 47

    Sandherr M, Einsele H, Hebart H. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:10511059.

    • Search Google Scholar
    • Export Citation
  • 48

    GlaxoSmithKline. Prescribing Information. ARZERRA (ofatumumab) Injection for Intravenous Infusion. Available at: http://us.gsk.com/products/assets/us_arzerra.pdf. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 49

    Genentech, Inc. Prescribing Information. Rituxan (rituximab) Injection for Intravenous Use. Available at: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf. Accessed April.

    • Search Google Scholar
    • Export Citation
  • 50

    Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:6869.

    • Search Google Scholar
    • Export Citation
  • 51

    Kim EB, Kim DS, Park SJ. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat 2008;40:3638.

    • Search Google Scholar
    • Export Citation
  • 52

    Koo YX, Tay M, Teh YE. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011;90:12191223.

    • Search Google Scholar
    • Export Citation
  • 53

    Matsue K, Kimura S, Takanashi Y. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:47694776.

    • Search Google Scholar
    • Export Citation
  • 54

    Niitsu N, Hagiwara Y, Tanae K. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:50975100.

    • Search Google Scholar
    • Export Citation
  • 55

    Pei SN, Chen CH, Lee CM. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255262.

    • Search Google Scholar
    • Export Citation
  • 56

    Carson KR, Evens AM, Richey EA. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:48344840.

    • Search Google Scholar
    • Export Citation
  • 57

    D’Souza A, Wilson J, Mukherjee S, Jaiyesimi I. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010;10:E19.

    • Search Google Scholar
    • Export Citation
  • 58

    Hopfinger G, Plessl A, Grisold W. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma 2008;49:23672369.

    • Search Google Scholar
    • Export Citation
  • 59

    Paues J, Vrethem M. Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 2010;48:291293.

    • Search Google Scholar
    • Export Citation
  • 60

    Reddy N, Abel TW, Jagasia M. Progressive multifocal leukoencephalopathy in a patient with follicular lymphoma treated with multiple courses of rituximab. Leuk Lymphoma 2009;50:460462.

    • Search Google Scholar
    • Export Citation
  • 61

    Rey J, Belmecheri N, Bouayed N. JC papovavirus leukoencephalopathy after first line treatment with CHOP and rituximab. Haematologica 2007;92:e101.

    • Search Google Scholar
    • Export Citation
  • 62

    Tuccori M, Focosi D, Maggi F. Progressive multifocal leukoencephalopathy: a report of three cases in HIV-negative patients with non-Hodgkin’s lymphomas treated with rituximab. Ann Hematol 2010;89:519522.

    • Search Google Scholar
    • Export Citation
  • 63

    Yokoyama H, Watanabe T, Maruyama D. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008;88:443447.

    • Search Google Scholar
    • Export Citation
  • 64

    Crippa F, Holmberg L, Carter RA. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002;8:281289.

    • Search Google Scholar
    • Export Citation
  • 65

    Rapoport AP, Miller Watelet LF, Linder T. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999;17:24462453.

    • Search Google Scholar
    • Export Citation
  • 66

    Ruescher TJ, Sodeifi A, Scrivani SJ. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998;82:22752281.

    • Search Google Scholar
    • Export Citation
  • 67

    Sonis ST, Oster G, Fuchs H. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:22012205.

    • Search Google Scholar
    • Export Citation
  • 68

    Straka C, Sandherr M, Salwender H. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood 2011;117:21212128.

    • Search Google Scholar
    • Export Citation
  • 69

    Mackall C, Fry T, Gress R. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 2009;44:457462.

    • Search Google Scholar
    • Export Citation
  • 70

    Tomblyn M, Chiller T, Einsele H. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:11431238.

    • Search Google Scholar
    • Export Citation
  • 71

    Winston DJ, Schiffman G, Wang DC. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 1979;91:835841.

  • 72

    Kulkarni S, Powles R, Treleaven J. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000;95:36833686.

    • Search Google Scholar
    • Export Citation
  • 73

    Meijer E, Dekker AW, Rozenberg-Arska M. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 2002;35:703712.

    • Search Google Scholar
    • Export Citation
  • 74

    Marr KA, Carter RA, Boeckh M. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:43584366.

    • Search Google Scholar
    • Export Citation
  • 75

    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309316.

    • Search Google Scholar
    • Export Citation
  • 76

    Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:11791187.

    • Search Google Scholar
    • Export Citation
  • 77

    Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med 1988;84:847854.

    • Search Google Scholar
    • Export Citation
  • 78

    Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:12011207.

    • Search Google Scholar
    • Export Citation
  • 79

    Razonable RR, Litzow MR, Khaliq Y. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002;34:14691474.

    • Search Google Scholar
    • Export Citation
  • 80

    Eleutherakis-Papaiakovou E, Kostis E, Migkou M. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 2010;85:863867.

    • Search Google Scholar
    • Export Citation
  • 81

    Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979995.

    • Search Google Scholar
    • Export Citation
  • 82

    Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007;59:522.

    • Search Google Scholar
    • Export Citation
  • 83

    Gafter-Gvili A, Fraser A, Paul M. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012;1:CD004386.

    • Search Google Scholar
    • Export Citation
  • 84

    Bucaneve G, Micozzi A, Menichetti F. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977987.

    • Search Google Scholar
    • Export Citation
  • 85

    Cullen M, Steven N, Billingham L. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988998.

    • Search Google Scholar
    • Export Citation
  • 86

    Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007;25:48214828.

    • Search Google Scholar
    • Export Citation
  • 87

    Bartlett JG, Perl TM. The new Clostridium difficile—what does it mean? N Engl J Med 2005;353:25032505.

  • 88

    Cook PP, Catrou P, Gooch M, Holbert D. Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006;64:348351.

    • Search Google Scholar
    • Export Citation
  • 89

    Loo VG, Poirier L, Miller MA. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:24422449.

    • Search Google Scholar
    • Export Citation
  • 90

    McDonald LC, Killgore GE, Thompson A. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:24332441.

  • 91

    Engelhard D, Cordonnier C, Shaw PJ. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002;117:444450.

    • Search Google Scholar
    • Export Citation
  • 92

    Youssef S, Rodriguez G, Rolston KV. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore) 2007;86:6977.

    • Search Google Scholar
    • Export Citation
  • 93

    Engelhard D, Akova M, Boeckh MJ. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:467470.

    • Search Google Scholar
    • Export Citation
  • 94

    Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001–2002, as part of the PROTEKT US study. J Antimicrob Chemother 2004;54(Suppl 1):i715.

    • Search Google Scholar
    • Export Citation
  • 95

    Kumashi P, Girgawy E, Tarrand JJ. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998–2002). Medicine (Baltimore) 2005;84:303312.

    • Search Google Scholar
    • Export Citation
  • 96

    Recommended adult immunization schedule: United States, 2012. Ann Intern Med 2012;156:211217.

  • 97

    Goodman JL, Winston DJ, Greenfield RA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845851.

    • Search Google Scholar
    • Export Citation
  • 98

    Slavin MA, Osborne B, Adams R. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995;171:15451552.

    • Search Google Scholar
    • Export Citation
  • 99

    Marr KA, Seidel K, Slavin MA. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:20552061.

    • Search Google Scholar
    • Export Citation
  • 100

    Rotstein C, Bow EJ, Laverdiere M. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331340.

    • Search Google Scholar
    • Export Citation
  • 101

    Kern W, Behre G, Rudolf T. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998;83:291301.

    • Search Google Scholar
    • Export Citation
  • 102

    Winston DJ, Chandrasekar PH, Lazarus HM. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495503.

    • Search Google Scholar
    • Export Citation
  • 103

    Bodey GP, Mardani M, Hanna HA. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380385.

    • Search Google Scholar
    • Export Citation
  • 104

    Koh LP, Kurup A, Goh YT. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002;71:260267.

    • Search Google Scholar
    • Export Citation
  • 105

    Marr KA, Crippa F, Leisenring W. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:15271533.

    • Search Google Scholar
    • Export Citation
  • 106

    Winston DJ, Maziarz RT, Chandrasekar PH. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705713.

    • Search Google Scholar
    • Export Citation
  • 107

    Marr KA, Leisenring W, Crippa F. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:15571559.

  • 108

    Bates DW, Su L, Yu DT. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:14521459.

  • 109

    Wingard JR, Kubilis P, Lee L. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:14021407.

    • Search Google Scholar
    • Export Citation
  • 110

    Rijnders BJ, Cornelissen JJ, Slobbe L. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:14011408.

    • Search Google Scholar
    • Export Citation
  • 111

    Perfect JR. Aerosolized antifungal prophylaxis: the winds of change? Clin Infect Dis 2008;46:14091411.

  • 112

    Astellas Pharma, Inc. Prescribing Information. MYCAMINE (micafungin sodium) For Injection; IV Infusion Only. Available at: http://www.astellas.us/docs/mycamine.pdf. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 113

    van Burik JA, Ratanatharathorn V, Stepan DE. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:14071416.

    • Search Google Scholar
    • Export Citation
  • 114

    Wingard JR, Carter SL, Walsh TJ. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:51115118.

    • Search Google Scholar
    • Export Citation
  • 115

    Cowen EW, Nguyen JC, Miller DD. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010;62:3137.

    • Search Google Scholar
    • Export Citation
  • 116

    McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007;44:e5556.

    • Search Google Scholar
    • Export Citation
  • 117

    Miller DD, Cowen EW, Nguyen JC. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010;146:300304.

    • Search Google Scholar
    • Export Citation
  • 118

    Krishna G, Moton A, Ma L. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958966.

    • Search Google Scholar
    • Export Citation
  • 119

    Vazquez JA, Skiest DJ, Nieto L. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:11791186.

    • Search Google Scholar
    • Export Citation
  • 120

    Cornely OA, Maertens J, Winston DJ. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348359.

    • Search Google Scholar
    • Export Citation
  • 121

    Schering Corporation, subsidiary of Merck & Co, Inc. Prescribing Information. NOXAFIL® (Posaconazole) ORAL SUSPENSION 40 mg/mL. Available at: http://www.spfiles.com/pinoxafil.pdf. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 122

    Bohme A, Just-Nubling G, Bergmann L. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996;38:953961.

    • Search Google Scholar
    • Export Citation
  • 123

    Pfizer, Inc. Prescribing Information. VFEND® (voriconazole) Tablets, Oral Suspension, and I.V. Available at: http://www.pfizer.com/files/products/uspi_vfend.pdf. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 124

    Weinberger M, Elattar I, Marshall D. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992;71:2443.

    • Search Google Scholar
    • Export Citation
  • 125

    Ullmann AJ, Lipton JH, Vesole DH. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335347.

    • Search Google Scholar
    • Export Citation
  • 126

    Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:23572362.

    • Search Google Scholar
    • Export Citation
  • 127

    Offner F, Cordonnier C, Ljungman P. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:10981103.

    • Search Google Scholar
    • Export Citation
  • 128

    Fukuda T, Boeckh M, Guthrie KA. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004;10:494503.

    • Search Google Scholar
    • Export Citation
  • 129

    Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980;142:338346.

    • Search Google Scholar
    • Export Citation
  • 130

    Saral R, Burns WH, Laskin OL. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:6367.

  • 131

    Saral R, Ambinder RF, Burns WH. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983;99:773776.

    • Search Google Scholar
    • Export Citation
  • 132

    Zaia J, Baden L, Boeckh MJ. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:471482.

  • 133

    Keating M, Coutre S, Rai K. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220227.

    • Search Google Scholar
    • Export Citation
  • 134

    Boeckh M, Kim HW, Flowers ME. Long–term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 2006;107:18001805.

    • Search Google Scholar
    • Export Citation
  • 135

    Erard V, Guthrie KA, Varley C. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110:30713077.

    • Search Google Scholar
    • Export Citation
  • 136

    Asano-Mori Y, Kanda Y, Oshima K. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83:472476.

    • Search Google Scholar
    • Export Citation
  • 137

    Oshima K, Takahashi T, Mori T. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 2010;12:421427.

    • Search Google Scholar
    • Export Citation
  • 138

    Schuchter LM, Wingard JR, Piantadosi S. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74:14241427.

  • 139

    Chanan-Khan A, Sonneveld P, Schuster MW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 140

    Reece DE, Rodriguez GP, Chen C. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:47774783.

    • Search Google Scholar
    • Export Citation
  • 141

    Tong Y, Qian J, Li Y. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007;82:403404.

  • 142

    Varettoni M, Vassallo C, Borroni G. Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol 2007;86:301302.

    • Search Google Scholar
    • Export Citation
  • 143

    Pour L, Adam Z, Buresova L. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009;9:151153.

    • Search Google Scholar
    • Export Citation
  • 144

    Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115:229232.

    • Search Google Scholar
    • Export Citation
  • 145

    George B, Pati N, Gilroy N. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010;12:322329.

    • Search Google Scholar
    • Export Citation
  • 146

    Beck JC, Wagner JE, DeFor TE. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010;16:215222.

    • Search Google Scholar
    • Export Citation
  • 147

    Milano F, Pergam SA, Xie H. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011;118:56895696.

    • Search Google Scholar
    • Export Citation
  • 148

    Montesinos P, Sanz J, Cantero S. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009;15:730740.

    • Search Google Scholar
    • Export Citation
  • 149

    Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant 1997;19:135142.

    • Search Google Scholar
    • Export Citation
  • 150

    Moretti S, Zikos P, Van Lint MT. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998;22:175180.

    • Search Google Scholar
    • Export Citation
  • 151

    Reusser P, Einsele H, Lee J. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:11591164.

    • Search Google Scholar
    • Export Citation
  • 152

    Ljungman P, Deliliers GL, Platzbecker U. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388392.

    • Search Google Scholar
    • Export Citation
  • 153

    Platzbecker U, Bandt D, Thiede C. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 2001;71:880885.

    • Search Google Scholar
    • Export Citation
  • 154

    Meyers JD, Reed EC, Shepp DH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:7075.

    • Search Google Scholar
    • Export Citation
  • 155

    Prentice HG, Gluckman E, Powles RL. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994;343:749753.

    • Search Google Scholar
    • Export Citation
  • 156

    Ljungman P, de La Camara R, Milpied N. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:30503056.

    • Search Google Scholar
    • Export Citation
  • 157

    Gentile G, Picardi A, Capobianchi A. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis 2006;6:167.

    • Search Google Scholar
    • Export Citation
  • 158

    Gimeno C, Solano C, Latorre JC. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008;46:33113318.

    • Search Google Scholar
    • Export Citation
  • 159

    Solano C, Munoz I, Gutierrez A. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001;39:39383941.

    • Search Google Scholar
    • Export Citation
  • 160

    Einsele H, Reusser P, Bornhauser M. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:30023008.

    • Search Google Scholar
    • Export Citation
  • 161

    Winston DJ, Baden LR, Gabriel DA. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2006;12:635640.

    • Search Google Scholar
    • Export Citation
  • 162

    Ayala E, Greene J, Sandin R. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851856.

    • Search Google Scholar
    • Export Citation
  • 163

    Busca A, de Fabritiis P, Ghisetti V. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007;9:102107.

    • Search Google Scholar
    • Export Citation
  • 164

    van der Heiden PL, Kalpoe JS, Barge RM. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006;37:693698.

    • Search Google Scholar
    • Export Citation
  • 165

    Bosi A, Bartolozzi B, Vannucchi AM. Polymerase chain reaction-based ”pre-emptive” therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica 2002;87:446447.

    • Search Google Scholar
    • Export Citation
  • 166

    Chakrabarti S, Collingham KE, Osman H. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001;28:879881.

    • Search Google Scholar
    • Export Citation
  • 167

    Winston DJ, Young JA, Pullarkat V. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111:54035410.

    • Search Google Scholar
    • Export Citation
  • 168

    Marty FM, Ljungman P, Papanicolaou GA. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11:284292.

    • Search Google Scholar
    • Export Citation
  • 169

    Nguyen Q, Champlin R, Giralt S. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999;28:618623.

    • Search Google Scholar
    • Export Citation
  • 170

    Boeckh M, Leisenring W, Riddell SR. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407414.

    • Search Google Scholar
    • Export Citation
  • 171

    Hakki M, Riddell SR, Storek J. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003;102:30603067.

    • Search Google Scholar
    • Export Citation
  • 172

    Gratama JW, van Esser JW, Lamers CH. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:13581364.

    • Search Google Scholar
    • Export Citation
  • 173

    Ozdemir E, St John LS, Gillespie G. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002;100:36903697.

    • Search Google Scholar
    • Export Citation
  • 174

    Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005;23:488496.

    • Search Google Scholar
    • Export Citation
  • 175

    O’Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125130.

    • Search Google Scholar
    • Export Citation
  • 176

    Yeo W, Chan PK, Ho WM. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927934.

    • Search Google Scholar
    • Export Citation
  • 177

    Sera T, Hiasa Y, Michitaka K. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721724.

    • Search Google Scholar
    • Export Citation
  • 178

    Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin’s lymphoma. Eur J Med Res 2008;13:483486.

    • Search Google Scholar
    • Export Citation
  • 179

    Westhoff TH, Jochimsen F, Schmittel A. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.

    • Search Google Scholar
    • Export Citation
  • 180

    Yeo W, Chan PK, Zhong S. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299307.

    • Search Google Scholar
    • Export Citation
  • 181

    Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:31473153.

    • Search Google Scholar
    • Export Citation
  • 182

    Brechot C, Degos F, Lugassy C. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270276.

    • Search Google Scholar
    • Export Citation
  • 183

    Dhedin N, Douvin C, Kuentz M. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616619.

    • Search Google Scholar
    • Export Citation
  • 184

    Evens AM, Jovanovic BD, Su YC. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:11701180.

    • Search Google Scholar
    • Export Citation
  • 185

    Vigano M, Vener C, Lampertico P. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011;46:125131.

    • Search Google Scholar
    • Export Citation
  • 186

    Hammond SP, Borchelt AM, Ukomadu C. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:10491059.

    • Search Google Scholar
    • Export Citation
  • 187

    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507539.

  • 188

    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:13351374.

  • 189

    Giaccone L, Festuccia M, Marengo A. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:809817.

    • Search Google Scholar
    • Export Citation
  • 190

    Lau GK, He ML, Fong DY. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702709.

    • Search Google Scholar
    • Export Citation
  • 191

    Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:5862.

    • Search Google Scholar
    • Export Citation
  • 192

    Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:9981005.

    • Search Google Scholar
    • Export Citation
  • 193

    Cortelezzi A, Vigano M, Zilioli VR. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006;35:467469.

    • Search Google Scholar
    • Export Citation
  • 194

    Peters MG, Hann Hw H, Martin P. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91101.

    • Search Google Scholar
    • Export Citation
  • 195

    Marcellin P, Heathcote EJ, Buti M. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:24422455.

    • Search Google Scholar
    • Export Citation
  • 196

    Leung N, Peng CY, Hann HW. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:7279.

    • Search Google Scholar
    • Export Citation
  • 197

    Chan HL, Heathcote EJ, Marcellin P. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745754.

    • Search Google Scholar
    • Export Citation
  • 198

    Ljungman P, Cordonnier C, Einsele H. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009;44:521526.

  • 199

    Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:148.

    • Search Google Scholar
    • Export Citation
  • 200

    Ortbals DW, Liebhaber H, Presant CA. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552557.

  • 201

    Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2006;12:143154.

    • Search Google Scholar
    • Export Citation
  • 202

    Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102:2730.

    • Search Google Scholar
    • Export Citation
  • 203

    Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001;7 Suppl:5S7S.

    • Search Google Scholar
    • Export Citation
  • 204

    Whimbey E, Champlin RE, Couch RB. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778782.

    • Search Google Scholar
    • Export Citation
  • 205

    Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977;39:350353.

  • 206

    Kempe A, Hall CB, MacDonald NE. Influenza in children with cancer. J Pediatr 1989;115:3339.

  • 207

    Elting LS, Whimbey E, Lo W. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995;3:198202.

    • Search Google Scholar
    • Export Citation
  • 208

    Fiore AE, Uyeki TM, Broder K. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:162.

    • Search Google Scholar
    • Export Citation
  • 209

    Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:18.

    • Search Google Scholar
    • Export Citation
  • 210

    Branson BM, Handsfield HH, Lampe MA. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:117; quiz CE11–14.

    • Search Google Scholar
    • Export Citation
  • 211

    Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:10521059.

    • Search Google Scholar
    • Export Citation
  • 212

    Hughes WT, Kuhn S, Chaudhary S. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:14191426.

  • 213

    Hughes WT, Rivera GK, Schell MJ. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:16271632.

    • Search Google Scholar
    • Export Citation
  • 214

    Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007;120:e4751.

    • Search Google Scholar
    • Export Citation
  • 215

    Marr KA, Bow E, Chiller T. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:483487.

  • 216

    Marras TK, Sanders K, Lipton JH. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis 2002;4:6674.

    • Search Google Scholar
    • Export Citation
  • 217

    Sangiolo D, Storer B, Nash R. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 2005;11:521529.

    • Search Google Scholar
    • Export Citation
  • 218

    Souza JP, Boeckh M, Gooley TA. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 1999;29:14671471.

    • Search Google Scholar
    • Export Citation
  • 219

    Vasconcelles MJ, Bernardo MV, King C. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 2000;6:3543.

    • Search Google Scholar
    • Export Citation
  • 220

    El-Sadr WM, Murphy RL, Yurik TM. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998;339:18891895.

    • Search Google Scholar
    • Export Citation
  • 221

    Madden RM, Pui CH, Hughes WT. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 2007;109:16541658.

    • Search Google Scholar
    • Export Citation
  • 222

    Schering Corporation, a subsidiary of Merck & Co, Inc. Prescribing Information. TEMODAR (temozolomide) Capsules; TEMODAR (temozolomide) for Injection Administered Via Intravenous Infusion. Available at: http://www.spfiles.com/pitemodar.pdf. Accessed October 16, 2012.

    • Search Google Scholar
    • Export Citation
  • 223

    Kritz A, Sepkowitz K, Weiss M. Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia. N Engl J Med 1991;325:661662.

    • Search Google Scholar
    • Export Citation
  • 224

    Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 1992;7:114121.

  • 225

    Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(Suppl 2):S416422.

  • 226

    Sepkowitz KA, Brown AE, Telzak EE. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832837.

  • 227

    Hahn T, Cummings KM, Michalek AM. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002;23:525531.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1346 955 83
PDF Downloads 312 218 19
EPUB Downloads 0 0 0